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Summary Clinical benefits have been shown to occur when using the long-acting b2-
agonist formoterol 4.5 mg for as-needed medication rather than terbutaline 500 mg in
patients with unstable asthma taking an inhaled corticosteroid. This study compared
their effects on health-related quality of life and the relation with conventional clinical
indices in the same population. 362 asthmatics were randomized to use either
formoterol 4.5mg or terbutaline 500mg as needed, both inhaled via Turbuhalers. The
Asthma Quality of Life Questionnaire (AQLQ) was practised at enrolment and
completed by 341 patients after randomization and at 4, 8, and 12 weeks. Clinical
indices were measured at the same time points. Mean overall AQLQ scores were
comparable at baseline, being 4.90 in the formoterol and 4.82 in the terbutaline group
and improved during treatment by 0.41 and 0.17 units, respectively (mean difference
0.24, 95% CI 0.08, 0.39, Po0:005). Mean improvement in the symptom domain was
0.49 units when using formoterol. Correlations between changes in clinical indices and
changes in AQLQ scores during the 12-week period were weak (maximum r value=0.37).
When used for as-needed medication, formoterol 4.5mg provided an improvement in
asthma-specific quality of life and to a somewhat greater extent than the widely used
terbutaline 500mg. The symptom domain in AQLQ showed almost 0.5 units
improvement after formoterol, a change that is considered to be clinically relevant.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
Over the last 10 years, health-related quality of life
(HRQL) has become an important outcome in
clinical studies and disease management programs
for various diseases, including asthma. Recognition
of the importance of HRQL, its weak correlation
with conventional clinical indices and the avail-
ability of validated HRQL instruments means that
many clinical studies now include patient HRQL
values as one of the end-points. Asthma-specific
HRQL measures have been developed over the past
few years, including the Asthma Quality of Life
Questionnaire (AQLQ), which has been used in
clinical studies worldwide.1 Several studies have
shown that the use of a long-acting b2-agonist twice
daily is associated with improvements in asthma-
related quality of life.2–6
ARTICLE IN PRESS
*Corresponding author. AstraZeneca R&D, Lund 221 87,
Sweden. Tel.: +46-46-33-64-69; fax: +46-46-33-75-53.
E-mail address: elisabeth.stahl@astrazeneca.com (E. St(ahl).
0954-6111/03/$ - see front matter r 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/S0954-6111(03)00138-0
Respiratory Medicine (2003) 97, 1061–1066
The use of short-acting b2-agonists for symptom
relief in patients with asthma is well established.
The long-acting b2-agonist formoterol has a rapid
onset similar to that of the short-acting b2-
agonists.7–10 Short-term studies showed its safety
when compared with the short-acting b2-agonists,
salbutamol and terbutaline.11,12 A recent long-term
study showed that formoterol reduces the number
of exacerbations and the time to the first exacer-
bation when used as-needed, without any safety
issues.13 This suggests that formoterol may be used
on an as-needed base. The current study investi-
gates the effects of formoterol and terbutaline as
needed on asthma-related quality of life in the
latter study, which included patients with moder-
ate to severe asthma not adequately controlled on
inhaled steroids alone.
Methods
The methodology of this double-blind, randomized,
parallel-group study has already been published.13
Patients (X18 years) with asthma for at least 6
months and treatment with a constant dose of
inhaled corticosteroids for at least 4 weeks
participated. The forced expiratory volume in
one second (FEV1) at baseline had to be >50%
predicted, with >12% increase after inhaling 1.5mg
terbutaline via Turbuhalers. The mean daily need
for rescue treatment (Bricanyls Turbuhaler
500 mg dose1) had to be 3–8 times/day on any 7
days of the 2-week run-in period. Approval was
obtained from regulatory agencies and ethics
committees at all the four centres, and patients
gave written informed consent.
Study design
Patients visited the clinic before and after a 2-week
run-in period, and after 4, 8 and 12 weeks
treatment. After run-in, patients were randomized
to use either 4.5 mg formoterol (Oxiss Turbuhaler)
or 500 mg terbutaline (Bricanyl Turbuhaler) for as-
needed medication during 12 weeks. Pre-broncho-
dilator FEV1 was measured at all visits. Severity of
asthma symptoms was rated on a 0–3 point scale
each morning and evening: 0=no symptoms, 3=se-
vere symptoms. Peak expiratory flow (PEF) was
recorded with a Vitalographs Peak Flow Meter
(Buckingham, UK).
Asthma Quality of Life Questionnaire (AQLQ)
Patients completed the self-administered AQLQ at
each clinic visit before any other measurements.1 A
practice questionnaire at the first visit was dis-
carded. Baseline values were obtained at the start
of the treatment period. The AQLQ comprises four
domains of HRQL: activity limitation (11 items),
symptoms (12 items), emotional function (5 items),
and environmental stimuli (4 items). Patients are
asked to recall their experiences during the
previous two weeks and score each item on a
7-point Likert scale: 1=severe, 7=no impairment.
Scores for the four domains and overall score are
computed as averages of the item scores. A change
of 0.5 point is judged as the minimal important
difference (MID).14,15
Statistical analysis
The analysis is based on all patients with health-
related quality of life data available after rando-
mization, using the last-value-carried-forward
principle to estimate missing values. The changes
in overall AQLQ scores from the start to the end of
treatment as well as changes in the four domain
scores were compared between treatment groups,
using analysis of variance with treatment and
centre as fixed factors and overall AQLQ score at
the start of treatment as covariate. Mean differ-
ences and 95% confidence limits between treat-
ments were calculated. The number needed to
treat (NNT) was calculated using the MID. The NNT
is the number of patients who need to be treated
with a new intervention (formoterol) for one
patient to have a clinically important improvement
over that which one would have experienced with
the control intervention (terbutaline). Associations
between changes in AQLQ scores and changes
in clinical indices over 12 weeks treatment
were examined using the Pearson’s correlation
coefficient.
Mean values of PEF and symptoms for the last 7
days in the run-in period and the last 28 days of the
treatment period were analysed. Mean change in
FEV1 from randomization to the last visit was
calculated.
Results
Of 362 patients randomly assigned to the two
treatment groups, 341 patients were eligible for
the AQLQ assessments. Demographic and baseline
data were comparable in the two groups (Table 1).
Changes in AQLQ
Baseline data for AQLQ score were similar in both
groups (Table 1). The overall AQLQ score improved
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during treatment (visit 2–visit 5) in both groups, with
a significantly greater improvement in the formoter-
ol group than in the terbutaline group (improvement
0.41 vs. 0.17, respectively, P ¼ 0:0003; Fig. 1). The
greatest improvements were seen in the symptom
domain of AQLQ, with a change of 0.49 in the
formoterol group and 0.21 in the terbutaline group
(P ¼ 0:002)(Fig. 2). The domain for emotional
function reached only a borderline significance
(increase of 0.37 in the formoterol group and 0.20
in the terbutaline group, P ¼ 0:074). 68 patients
(38%) in the formoterol group and 51 (29%) in the
terbutaline group increased in the overall score of
AQLQ more than 0.5 unit. The NNT for the
formoterol group was 9.1 with regard to the overall
AQLQ and 7.7 for the symptom domain of the AQLQ.
Changes in clinical characteristics
Mean morning and evening PEF and symptoms were
similar in both groups during the run-in period.
Mean morning and evening PEF improved signifi-
cantly more in the formoterol group than in the
terbutaline group during the study (P ¼ 0:009 and
0:043; respectively). Improvements in symptoms
were similar in the two groups (Table 2). Mean FEV1
changed from 2.31 L at the start of the study to
2.38 L at the last visit in the formoterol group and
from 2.20 to 2.18 L in the terbutaline group, the
difference between the groups being statistically
significant (mean ratio 105%, 95% CI 101, 108,
P ¼ 0:004). The mean number of rescue inhalation
medications fell more in the formoterol group than
in the terbutaline group (1.15 inhalations vs. 0.40
inhalations, and mean change 0.76, 95% CI 1.18,
0.33, P ¼ 0:0005).
Correlations
Correlations between changes in AQLQ scores and
changes in the clinical measures were weak to
moderate, both for overall scores and for the
specific AQLQ domains (Table 3, Fig. 3).
Discussion
The present study shows that use of for-
moterol 4.5 mg as-needed medication in patients
inadequately controlled when using inhaled corti-
costeroids improves HRQL to a greater extent than
the use of terbutaline 500 mg. The two groups were
comparable with regard to the doses of inhaled
corticosteroids. Formoterol improved overall HRQL
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Table 1 Patient characteristics at baseline.
Variable Formoterol Terbutaline
Number of patients 182 180
Men/women (no.) 88/94 69/111
Age (years) 46 (18–70) 48 (18–75)
Duration of asthma (years) 16 (1–66) 17 (1–60)
FEV1 (L) 2.36 (1.13–4.30) 2.27 (1.00–4.65)
FEV1 (% predicted) 73.7 (4–162) 74.2 (40–130)
Reversibility (% from baseline) 19 (2–77) 19 (3–98)
Inhaled daily steroid dose (mg) 890 (200–2800) 860 (100–2400)
AQLQ
Overall 4.90 4.82
Activity limitation 4.82 4.67
Symptoms 4.81 4.75
Emotional function 5.35 5.35
Environmental exposure 4.85 4.78
Values are presented as means with ranges between brackets=( ).
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Figure 1 Mean values (7SEM) in overall AQLQ from
baseline to week 12. Higher score means better HRQL.
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compared with baseline and each of the domains of
the AQLQ as well (symptoms, activity limitation,
emotional function and environmental exposure).
Mean improvement in the symptom domain was
almost 0.5 units (0.49), a change that patients
consider being important and which therefore can
be interpreted as clinically relevant. The overall
score for improvement in AQLQ was 0.41 in
the formoterol group. The NNT calculation showed
that the number for this overall AQLQ was 9.1
for the formoterol group. This means that one in
nine patients experienced a clinically important
improvement in their HRQL over and above that
which they would have had using terbutaline as
needed. The NNT for the formoterol group was 7.7
(eight patients) for the symptom domain of AQLQ.
The reason for the improvement in HRQL when
using a long-acting instead of a short-acting b2-
agonist can be debated. Patients required their
inhalers less often with formoterol and were
thus not reminded about having asthma as fre-
quently, although the difference between the two
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Figure 2 Mean values (7SEM) in symptoms, activity limitation, emotional function, environmental exposure in AQLQ
from baseline to week 12. Higher score means better HRQL.
Table 2 Change in asthma control, diary variables, during formoterol and terbutaline treatment for 12 weeks.
n Formoterol Terbutaline Formoterol-terbutaline
Baseline Treatment Change Baseline Treatment Change Mean change 95% CI P-value
Symptoms day
(score 0–3)
1.18 0.99 0.20 1.21 1.04 0.17 0.04 0.15, 0.08 0.5
Symptoms night
(score 0–3)
0.51 0.44 0.08 0.55 0.49 0.06 0.02 0.11, 0.07 0.7
PEF morning
(l/min)
369 376 8 357 354 4 11 3,20 o0.01
PEF evening
(l/min)
387 391 3 376 373 5 8 0,15 o0.05
nAdjusted mean values.
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treatments was not large.13 Another reason could
be that the long duration of formoterol may result
in a better exercise tolerance and thus increase the
patient’s HRQL. Better stabilization of the airway
function with better PEF values may also have
affected patient’s HRQL, as will have the decrease
in the number of exacerbations.13 The difference in
improvements in PEF between the groups was
small; however, the favour was for formoterol.
Long-acting b2-agonists have been shown to
improve cognitive performance in patients with
nocturnal asthma, who then sleep better through
the night.16 In our study, nocturnal symptoms did
not improve to a larger extent than daytime
symptoms and correlations between nocturnal
symptoms and HRQL scores were weak. The
improved HRQL with formoterol is therefore not
easily explained by better asthma control at night.
Our data suggest that, in patients with asthma
who are still unstable despite adequate doses of an
inhaled corticosteroid, the use of formoterol as
needed may be preferable to terbutaline as-needed
ARTICLE IN PRESS
Table 3 Correlation coefficients (r) between change in HRQL measures and changes in FEV1, symptoms and PEF
with treatment.
Overalln Activityn Symptomsn Emotionsn Environmentn
FEV1 (L)
n 0.15 0.11 0.19 0.08 0.07
Symptomsw (day) 0.37 0.30 0.42 0.21 0.23
Symptomsw (night) 0.29 0.22 0.34 0.19 0.13
PEFw (morning) 0.24 0.19 0.27 0.17 0.14
PEFw (evening) 0.24 0.17 0.29 0.16 0.13
nMean change from visit 2 to visit 5.
wMean change from run-in to end of treatment.
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Figure 3 (a) Plot of change in AQLQ, overall vs. change in FEV1. (b) Plot of change in AQLQ, overall vs. change in PEF.
(c) Plot of change in AQLQ, overall vs. change in symptoms.
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from a patient’s point of view. Although there was
an overall improvement in mean AQLQ scores and
clinical measures of asthma control, the pattern
within patients varied greatly as shown by the weak
correlations between the changes in clinical mea-
surements and AQLQ scores (Table 3; Fig. 3a–c).
These data emphasize the fact that the benefits
perceived by patients cannot be derived from
spirometry or symptom scores, but are manifested
in patients’ day-to-day functioning. No single
conventional clinical variable correlated well with
HRQL data, as has been shown in previous studies
including the 1-year FACET study.17 Other publica-
tions have shown weak correlations between HRQL
and FEV1.
18,19 There must presumably be differ-
ences in patients’ perception of changes in their
airway calibre or in their lifestyle to explain the
weak correlation between FEV1 and AQLQ scores.
This means that patients with the same change in
FEV1 may be affected by their disease with a great
variation and if so score their HRQL differently. This
scenario has also been highlighted in a paper by
Juniper.20
It has to be emphasized that the patients in the
present study all received moderate to high doses
of inhaled corticosteroids and in addition had a
daily need for rescue treatment of at least three
times/day at randomisation, which means that
according to present guidelines, this patient group
would be prescribed a maintenance use of long-
acting b2-agonists.
In conclusion, this study has shown that formo-
terol 4.5 mg when used for as-needed medication
provides an improvement in asthma-specific quality
of life and to a somewhat greater extent than the
widely used rescue medication, terbutaline 500 mg.
The main benefit from formoterol was seen in the
symptom domain. Further studies in patients with
mild to moderate asthma are needed to confirm the
use of an as-needed treatment with the rapid- and
long-acting b2-agonist, formoterol, as an alterna-
tive to the rapid- and short-acting b2-agonists.
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